Growth Hormone (GH) Treatment Decreases Plasma Kisspeptin Levels in GH-Deficient Adults with Prader-Willi Syndrome.
Prader–Willi Syndrome
growth hormone deficiency
kisspeptin
leptin
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
09 Jul 2021
09 Jul 2021
Historique:
received:
12
06
2021
revised:
06
07
2021
accepted:
08
07
2021
entrez:
24
7
2021
pubmed:
25
7
2021
medline:
25
7
2021
Statut:
epublish
Résumé
Obesity and growth hormone (GH)-deficiency are consistent features of Prader-Willi syndrome (PWS). Centrally, kisspeptin is involved in regulating reproductive function and can stimulate hypothalamic hormones such as GH. Peripherally, kisspeptin signaling influences energy and metabolic status. We evaluated the effect of 12-month GH treatment on plasma kisspeptin levels in 27 GH-deficient adult PWS patients and analyzed its relationship with metabolic and anthropometric changes. Twenty-seven matched obese subjects and 22 healthy subjects were also studied. Before treatment, plasma kisspeptin concentrations in PWS and obese subjects were similar (140.20 (23.5-156.8) pg/mL vs. 141.96 (113.9-165.6) pg/mL, respectively,
Identifiants
pubmed: 34300220
pii: jcm10143054
doi: 10.3390/jcm10143054
pmc: PMC8306252
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Instituto de Salud Carlos III
ID : PI18/00734
Organisme : Fundació Parc Taulí
ID : CIR2018/001
Références
Reprod Sci. 2017 Feb;24(2):227-233
pubmed: 27313117
Neth J Med. 2015 May;73(4):175-8
pubmed: 25968289
Nat Rev Endocrinol. 2014 Sep;10(9):511
pubmed: 24981460
Ann Endocrinol (Paris). 2019 Feb;80(1):38-46
pubmed: 30243474
Growth Horm IGF Res. 2004 Feb;14(1):1-15
pubmed: 14700552
Actas Esp Psiquiatr. 2019 May;47(3):79-87
pubmed: 31233206
Peptides. 2021 Jan;135:170433
pubmed: 33129892
J Int Neuropsychol Soc. 2021 Mar 04;:1-13
pubmed: 33660593
Diabetologia. 1985 Jul;28(7):412-9
pubmed: 3899825
Endocrinol Diabetes Nutr (Engl Ed). 2018 Apr;65(4):229-236
pubmed: 29510967
Neuroendocrinology. 2010;91(4):302-7
pubmed: 20628262
Front Endocrinol (Lausanne). 2018 Apr 24;9:184
pubmed: 29740399
Int J Endocrinol. 2019 Dec 1;2019:1347208
pubmed: 31871451
PLoS One. 2017 Jun 21;12(6):e0179834
pubmed: 28636637
Peptides. 2011 Sep;32(9):1781-6
pubmed: 21827808
Reprod Fertil Dev. 2017 Nov;29(12):2466-2478
pubmed: 28610651
J Clin Endocrinol Metab. 2014 May;99(5):1816-24
pubmed: 24471571
Am J Med Genet A. 2007 Mar 1;143A(5):443-8
pubmed: 17103437
Horm Mol Biol Clin Investig. 2016 Feb;25(2):91-119
pubmed: 26953710
J Clin Endocrinol Metab. 2013 Jun;98(6):E1072-87
pubmed: 23543664
Ther Clin Risk Manag. 2016 Jun 02;12:873-81
pubmed: 27330297
Growth Horm IGF Res. 2011 Aug;21(4):185-90
pubmed: 21664161
Nature. 1998 Oct 22;395(6704):763-70
pubmed: 9796811
Clin Endocrinol (Oxf). 2000 Jan;52(1):101-5
pubmed: 10651760
Growth Horm IGF Res. 2003 Dec;13(6):322-7
pubmed: 14624765
Adv Exp Med Biol. 2013;784:363-83
pubmed: 23550015
Clin Endocrinol (Oxf). 2012 Jul;77(1):86-93
pubmed: 22117629
J Endocrinol Invest. 2021 Mar;44(3):621-629
pubmed: 32720093
Front Synaptic Neurosci. 2013 Aug 06;5:3
pubmed: 23964236
Front Endocrinol (Lausanne). 2018 Apr 16;9:145
pubmed: 29713310
Endocrinol Diabetes Nutr (Engl Ed). 2019 Nov;66(9):579-587
pubmed: 31006652
Curr Genomics. 2011 May;12(3):204-15
pubmed: 22043168
Mol Cell Endocrinol. 2016 Dec 15;438:100-106
pubmed: 27477782
Genet Med. 2012 Jan;14(1):10-26
pubmed: 22237428
Brain Res. 2010 Dec 10;1364:129-38
pubmed: 20800054
Int J Endocrinol. 2016;2016:6790794
pubmed: 27990162
Endocr Pract. 2016 Oct;22(10):1235-1244
pubmed: 27409821
Hormones (Athens). 2017 Jan;16(1):33-41
pubmed: 28500826
Diabetes Obes Metab. 2018 Dec;20(12):2800-2810
pubmed: 29974637